

## Index

absence epilepsy see childhood absence epilepsy; anoxic seizures, reflex 2, 34, 76 juvenile absence epilepsy antidepressants, interactions with 118 absence status 128-9 antiepileptic drugs (AEDs) absences (absence seizures) 32-3, 39-40 adolescent-onset epilepsies 88-92 atypical, Dravet syndrome 12 appropriate use 138, 141 differential diagnosis 40 childhood-onset epilepsies 53-4, 54-5, 55 accidental deaths 47, 109-10 combination therapy 22-3, 46, 89, 97, 138 accidents 47-8, 109-10 compliance or adherence 20, 45-6, 91-2 acetazolamide 96 duration of treatment 56-7, 90 ACTH therapy 17-18, 62-3 failure of first choice 22-3, 53 acute presentation of seizures 30-1 further trials 58 generic and proprietary forms 89-90 acute symptomatic seizures 1, 5, 30 infant-friendly formulations 16 adherence see compliance adolescent-onset epilepsies 73-105 infantile epilepsies 15-16 cognitive and social outcomes 99-100 missed doses 46 common epilepsy syndromes 79-88 refractory epilepsy see intractable epilepsy diagnostic problems 74-9 relapse risk after withdrawal 57, 90, 112-13 drug treatment 88-92 risks and hazards 115-19 restrictions 92 serum concentration monitoring 16, 46 treatment 95-9 side-effects see side effects of antiepileptic drugs triggers 92-5 withdrawal 57, 90-1, 112-13 anxiety 49, 51, 120 adolescents effects of puberty on established epilepsy 74 astatic seizures 42 incidence of epilepsy 73-4, 74 Atkins diet, modified 24 management of cognitive and behavior atonic seizures 42, 43 problems 101 attention deficit hyperactivity disorder (ADHD) transition to adult epilepsy services 102-4 49, 50, 120 adrenoleucodystrophy 88 atypical benign partial epilepsy of adverse effects of antiepileptic drugs see side effects childhood 58 of antiepileptic drugs aura 83-4, 85 adversive seizures 37 autism 51-2 alcohol use 93-4 automatisms 84, 85 Alpers' disease 16, 22, 116 autonomic symptoms 41, 84 anger, paroxysmal 36-7 autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) 36 anoxic epileptic seizure 34

bathing 47, 109	prognosis 64–5, 66, 80
Batten's disease 22	childhood occipital epilepsy
behavior problems 49, 50, 100, 121	early-onset see Panayiotopoulos syndrome
antiepileptic drug-related 118–19	late-onset 41–2
management in adolescents 101	childhood-onset epilepsies (2 to 12 years) 29-45
behaviors, abnormal paroxysmal 36–8	acute presentation of seizures 30–1
benign epilepsy of childhood with centro-	clinical history 29–30
temporal spikes (BECTS) 3, 40–1	co-morbidities 48–52
management 55, 56	first-line medication 53, 54, 55
onset of puberty and 74	later management 63
prognosis 63–4, 65, 66, 111	middle management 45–55
benign familial neonatal–infantile seizures 15	presentations and differential diagnoses 32
benign focal epilepsies of childhood 40–2	prognosis 63–6
benign infantile epilepsies 14–15, 20, 26–7	relapse after withdrawal of medication 57
benign infantile epitepsies 14–13, 20, 20–7 benign infantile seizures 14–15, 26–7	safety restrictions 47–8
	specific epilepsies 39–44
benign myoclonic epilepsy of infancy 15, 27, 111	chromosomal disorders 8
benign partial epilepsy with occipital paroxysms	
(BEOP) 41–2	clinical presentation of epilepsy 1
benign rolandic epilepsy of childhood (BREC)	clobazam
see benign epilepsy of childhood with	adolescent-onset epilepsies 81, 89
centro-temporal spikes	childhood-onset epilepsies 54, 55
benzodiazepines	in Dravet syndrome 19
infantile epilepsies 19	co-morbidities 21, 48–52, 99
prolonged seizures 115, 126	cognitive delay 49–50
side effects 118	see also developmental regression
status epilepticus 113–14, 126, 130–1	cognitive effects of antiepileptic drugs 118–19
bicycles 48, 109	cognitive outcome, long-term 65–6, 99–100
biotidinase deficiency 9	compliance (adherence) 20, 45–6, 91–2
blank spells 32–3	computed tomography (CT) 3–4, 31
bone health 47–8, 94, 117	congenital malformations 54, 117–18
brain lesions, structural 6, 7–8	coning 30
brain tumors 7, 24	continuous spike-wave of slow-sleep (CSWSS) 38,
burns 47–8, 109	52, 58, 129, 130
1 47 0 04 117	contraception 94–5
calcium supplements 47–8, 94, 117	corpus callosotomy 60–1
carbamazepine	cortical dysplasia 59
adolescent-onset epilepsies 81, 89, 95–6	corticosteroid therapy 17–18, 62–3
childhood-onset epilepsies 55	cycling 48, 109
exacerbation of seizures 52	
infantile epilepsies 16	dentatorubro-pallidoluysian atrophy
side effects 116	(DRPLA) 88
cardiac arrhythmias 77, 139	depression 49, 51, 78, 120
cardiogenic syncope 34, 77, 139	developmental regression
carpet burns 2	in childhood epilepsies 38–9
catamenial epilepsy 94	in Dravet syndrome 12, 26
cataplexy 37	in infantile epilepsies 21
catastrophic epilepsy 6	in migrating partial seizures in infancy
cause of epilepsy, failure to look for underlying	13–14
134, 140–1	in West syndrome 10–11, 21, 26
channelopathies 12–13, 15	see also learning difficulties
Charlie Foundation 62	diagnosis of epilepsy 1-4
child abuse 78	childhood-onset epilepsies 29-30
childhood absence epilepsy (CAE) 39-40	in adolescents 74–9



diagnosis of epilepsy (cont.)	non-epileptic attack disorder 77–8
incorrect 139	transition to adult epilepsy services and
prevention of wrong 134	103–4
reviewing 52	family history 6
diazepam, rectal 115, 126	fear, paroxysmal 37
Doose syndrome see myoclonic-astatic epilepsy	febrile seizures 5, 30–1
Down syndrome (trisomy 21) 8, 21	Dravet syndrome 12
Dravet syndrome (severe myoclonic	investigations 30-1
epilepsy of infancy) 12-13	prevention 136–7
ketogenic diet 25, 61	felbamate 54, 117
prognosis 26, 111	first aid, seizure 114
treatment 19, 20, 22, 58	first unprovoked seizures 2, 110-11
drop attacks, epileptic 33, 42, 43, 109	focal (partial) epilepsies
drowning 47, 109	adolescent-onset 82-6, 95-6
dual pathology 59	childhood-onset 58
dysembryoblastic neuroepithelial tumor (DNET) 59	social and cognitive outcomes 100-1
	see also idiopathic partial epilepsies;
EEG see electroencephalography	symptomatic partial epilepsies
electrical status epilepticus of slow-wave sleep	focal (partial) seizures
(ESESS) 38, 130	absences 40
management 52, 62-3	in adolescents 83
prognosis 66	in childhood 33, 37
electrocardiogram (ECG) 77	in infants 5
electroencephalography (EEG)	with normal imaging 44
invasive monitoring 59	folic acid supplements 54, 94, 118
misinterpretation 52, 140	fosphenytoin 127
role 2–3	fractures 47–8
encephalitis 135	frontal lobe epilepsy/seizures 36, 85-6
epilepsia partialis continua (EPC) 131	functional neuro-imaging 85
epilepsy, defined 1	0 0
epilepsy surgery 23–4, 97–9, 61	GABA-B gene mutations 13
epilepsia partialis continua 131	gabapentin
palliative 23, 60–1	focal epilepsies 55, 95–6
resective 23, 60	side effects 118
withdrawal of medication after 57	worsening of epilepsy 53
epilepsy syndromes 3	GABRG2 gene mutations 42
common, in early infancy 9–14	generalized epilepsy with febrile seizures plus
presenting in adolescence 79–88	(GEFS+) 40, 42, 136
presenting in childhood 39–44	generalized tonic-clonic seizures (GTCS)
usefulness of concept 39	in childhood absence epilepsy 40
epilepsy with grand mal on awakening 79	in infants 5
epileptic encephalopathy 6, 42–4, 62–3	in juvenile myoclonic epilepsy 79, 80
epileptic spasms 45	versus syncope 34–5
episodic dyscontrol disorder 36–7	genetic disorders 6
ethosuximide 54	gingival hyperplasia 117
eyelid myoclonia with absences 40	glucose transporter-1 (GLUT-1) deficiency 9, 14
ejena mjesiona war assences is	24, 61
falls 33	21, 01
non-epileptic 33	hallucinations 37
with abnormal movements or convulsions 33–4	hazards of epilepsy <i>see</i> risks and hazards of
family	epilepsy
adjustment 21, 121	head injuries 47–8, 109, 135–6
information provision 141	helmets 47, 109

hematological disorders, drug-induced 116	prognosis 65
hemiconvulsion, hemiplegia and epilepsy (HHE)	juvenile myoclonic epilepsy (JME) 79–82
113	effect of puberty on incidence 73-4
history, clinical 2, 3, 29-30, 74-5	management 81–2
hormonal treatment, West syndrome 17–18, 23	outcomes 99–100, 111–12
hypoxic–ischemic encephalopathy, neonatal 20, 135	photosensitivity 87, 92
hypsarrhythmia 11, 129	risk of relapse 81–2, 112
treatment 16, 17	seizure types 40, 79
treatment 10, 17	versus progressive myoclonic epilepsy 86–7
idiopathic childhood occipital epilepsy of Gastaut	versus progressive injudionic epitepsy ou 7
41–2	ketogenic diet 24–5, 55, 61–2
idiopathic generalized epilepsies (IGE)	in adolescence 96
adolescent-onset 79–82	in non-convulsive status epilepticus 131
childhood-onset 53–4, 65	in non-convuisive status epitepticus 151
otherwise unclassifiable 79	lacosamide 55
idiopathic partial epilepsies, childhood-onset 53,	Lafora body disease 87
55, 64, 66	lamotrigine
immunizations 20–1	adolescent-onset epilepsies 81, 89, 95–6
inborn errors of metabolism 8–9, 22	childhood-onset epilepsies 53, 54, 55
incontinence 2	side effects 116
independence, limitations to 48	Landau-Kleffner syndrome (LKS) 38, 58, 63, 129
infantile epilepsies 5–27	130
benign 14–15, 20, 26–7	learning difficulties 21, 49-50, 65, 100
co-morbidities 21	management in adolescents 101
common syndromes 9–14	transition to adult epilepsy services 103-4
early treatment 15–20	see also developmental regression
epilepsy surgery 23–4	Lennox-Gastaut syndrome (LGS) 43-4
family adjustment 21	management 54, 61, 63
incidence 5	prognosis 65, 66, 111
ketogenic diet 24-5	levetiracetam
middle treatment 20-5	childhood-onset epilepsies 54, 55
prognosis 25–7	infantile epilepsies 16
symptomatic 6–9	side effects 118
infantile seizures, benign 14–15, 26–7	status epilepticus 127
infantile spasms 5, 10, 11–12	liver toxicity 116–17
see also West syndrome	lumbar puncture 30–1
infections, central nervous system 135	•
information provision, to families 141	magnetic resonance imaging (MRI) 3-4
injuries, physical 47–8, 109–10	adolescent-onset epilepsies 84–5
intellectual disability see learning difficulties	childhood-onset epilepsies 31, 44
intensive care (therapy) unit 128, 131	misinterpretation 140
intermittent explosive disorder 36–7	pre-surgical 59
intracranial pressure, acutely raised 30	magnetic resonance spectroscopy (MRS) 85
intractable (medically refractory) epilepsy 23, 57–8	male reproductive function 95
incorrect labeling 140	mannerisms 35
perceived impact of 121–2	marijuana use 93–4
predictors 64	Matthews Friends 62
risk of 113	
	medically refractory epilepsy <i>see</i> intractable
see also epilepsy surgery	epilepsy
intravenous immunoglobulin (IVIG) 63, 131	medication dispensers 46
	medico-legal aspects 139–42
juvenile absence epilepsy (JAE) 40, 79	medium chain triglycerides (MCT) 24
effect of puberty on incidence 73-4	meningitis 135

menstruation 94	obesity 119
mental handicap/retardation see learning	oral contraceptive pill 94, 96, 117
difficulties	oxcarbazepine 55, 95–6
metabolic disorders 8-9, 22	
methylphenidate 50	Panayiotopoulos syndrome (early-onset benign
methylprednisolone 62–3	occipital epilepsy) 41
midazolam	management 55
buccal 115, 126	prognosis 63–4, 111
intravenous infusion 128	parasomnias 35–6
migrating partial seizures in infancy (MPSI)	paroxysmal disorders, non-epileptic 75–9
13–14, 25, 26	partial epilepsies see focal epilepsies
missed doses 46	partial seizures see focal seizures
mitochondrial diseases 88	perioral myoclonia with absences 40
molecular testing 13	phenobarbital
Morrell's procedure (multiple subpial transection)	in Dravet syndrome 19
61, 130	side effects 116, 117–18
mortality risks 110, 113	phenytoin 22, 89, 97
motor behaviors, bizarre 37	side effects 116, 117–18
movement abnormalities, paroxysmal 35	status epilepticus 127
multiple ligation-dependent probe amplification	photoparoxysmal response (PPR), Dravet
(MLPA) 8	syndrome 13
multiple subpial transection (MST) 61, 130	photosensitivity 87, 92
myoclonic-astatic epilepsy (MAE) (Doose	piracetam 96–7
syndrome) 40, 42-3	polypharmacy 22-3, 46, 89, 97, 138
management 61	positron emission tomography (PET) 85
prognosis 65, 66	post-traumatic epilepsy (PTE) 135-6
myoclonic epilepsies	prednisone/prednisolone 17-18, 62-3
benign, of infancy 15, 27, 111	pregnancy 54, 81, 94, 117-18
juvenile see juvenile myoclonic epilepsy	prevention 133–8
progressive (PME) 58, 86-8, 96-7	primary and severe familial epilepsies 134
severe, of infancy see Dravet syndrome	secondary epilepsies 135–7
myoclonic seizures 5, 12	wrong diagnosis 134
myoclonus 80, 87	wrong treatment 137–8
	progressive myoclonic epilepsies (PME) 58, 86-8
narcolepsy 37	96–7
National Institute for Health and Clinical	propofol 128, 131
Excellence (NICE) 88, 90, 142	provocative stimuli, avoidance of 92-3
neonatal hypoxic-ischemic encephalopathy 20,	provoked seizures see symptomatic seizures
135	pseudo-epileptic seizures see non-epileptic attack
neonatal-infantile seizures, benign familial 15	disorder
neuro-degenerative disorders 22, 43	psychogenic non-epileptic seizures (PNES)
neuro-glycopenia 9	see non-epileptic attack disorder
neuro-imaging 3–4	psychological problems 120–1
acute seizures 31	psychosis 49, 51, 118
adolescent-onset epilepsies 83	psychosocial risks and hazards of epilepsy 119-22
functional 85	puberty
neuronal ceroid lipofuscinosis, juvenile 88	effects on established epilepsy 74
night terrors 35–6, 85	incidence of epilepsy during 73-4, 74
nitrazepam, West syndrome 19	purple hand/glove syndrome 127
non-epileptic attack disorder (NEAD) 35,	pyridoxine dependency 9, 19
77–5	pyruvate dehydrogenase complex deficiency 24, 6
non-epileptic paroxysmal disorders 75–9	
nurseries 20	quality of life 119–21

rage, paroxysmal 36-7	dose-related 115-16
rashes, drug-induced 116	idiosyncratic reactions 116-17
Rasmussen's syndrome 63, 98, 111, 131	in infancy 16, 22
recreational drug use 93–4	long-term 117
recurrence risks	teratogenicity 117–18
after AED withdrawal 57, 90, 112-13	weight gain and obesity 119
seizures 2, 110–11	single photon emission computed tomography
reflex anoxic seizures 2, 34, 76	(SPECT) 85
refractory epilepsy see intractable epilepsy	sleep
regression see developmental regression	deprivation 93
remission, likelihood of 111–12	disruption 49, 51
restrictions, safety 47–8, 92, 109–10	events during 35–6
ring chromosome 20 8	social growth, limitations to 48
risks and hazards of epilepsy 108–23	social isolation 101, 122
antiepileptic medication 115–19	social outcome, long-term 99-100, 122, 66
minimizing 114–15	sodium valproate see valproic acid/sodium
perception and prevention 123	valproate
psychosocial 119–22	sports participation 48
seizure-related 109–14	staring episodes 32–3
road traffic accidents, prevention 136	status epilepticus 126–31
Royal College of Paediatrics and Child Health	convulsive (CSE) 126–8
(RCPCH) 89	inappropriate management 141
rufinamide 54	management 126–8, 137
Tulliallide 34	refractory (RCSE) 128
school 78, 121	risks 113–14
SCN1A gene mutations 12, 13, 42	non-convulsive (NCSE) 37, 128–31
SCN1A-related epileptic encephalopathies 12–13	failure to diagnose 140
SCN1B gene mutations 42	treatment to minimize risks 114–15
SCN2A gene mutations 15	stereotypies 35
SCN2B gene mutations 13	steroid therapy <i>see</i> corticosteroid therapy
Scottish Intercollegiate Guidelines Network	Stevens–Johnson syndrome 116
	stimulant medications 50
(SIGN) 88, 142 seizures	
	stiripentol, in Dravet syndrome 19 stress 93
acute presentation 30–1	
clinical diagnosis 2	structural brain lesions 6, 7–8
first aid for 114	Sturge–Weber syndrome 24, 98, 111
first unprovoked 2, 110–11	subacute sclerosing panencephalitis (SSPE) 88
inaccurate classification 140	submersion injuries 47, 109
minor 2	sudden unexpected (or unexplained) death in
presentation and differential diagnosis 32	epilepsy (SUDEP) 110, 141
prolonged, treatment 114–15	suicide risk 118
risks and hazards related to 109–14	sulthiame 55
symptomatic see symptomatic seizures	surgery, epilepsy see epilepsy surgery
triggers 92–5	swimming 47, 109
self-empowerment 102	symptomatic epilepsies 6–9, 44
self-esteem, poor 120	symptomatic generalized epilepsies
severe myoclonic epilepsy of infancy (SMEI)	childhood-onset 53, 54–5, 62–3
see Dravet syndrome	prognosis 65, 66
sexual abuse 78	symptomatic focal (partial) epilepsies
sexuality 94–5	childhood-onset 53, 55, 61
side effects of antiepileptic drugs 115-19, 138	prognosis 65, 66
assessment 46	symptomatic seizures
cognitive and behavioral 51, 118-19	acute 1, 5, 30